Bruton tyrosine kinase mediatesTLR9-dependent human dendritic cell activation

Background Bruton tyrosine kinase (BTK) plays an essential role in various biologic functions of different cell types. Mutations in BTK lead to X-linked agammaglobulinemia (XLA) in humans. BTK was recently linked to the innate immune system, in particular, the Toll-like receptor (TLR) pathway; howev...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2014-06, Vol.133 (6), p.1644
Main Authors: Lougaris, Vassilios, Baronio, Manuela, Vitali, Massimiliano, Tampella, Giacomo, Cattalini, Marco, Tassone, Laura, Soresina, Annarosa, Badolato, Raffaele, Plebani, Alessandro
Format: Article
Language:English
Subjects:
Biomedical research
Cell culture
Cytokines
Flow cytometry
Immune system
Life sciences
Patients
Software
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Bruton tyrosine kinase (BTK) plays an essential role in various biologic functions of different cell types. Mutations in BTK lead to X-linked agammaglobulinemia (XLA) in humans. BTK was recently linked to the innate immune system, in particular, the Toll-like receptor (TLR) pathway; however, the TLR9 pathway has never been studied in dendritic cells (DCs) of patients with XLA. Objective The aim of this study was to investigate the role of BTK in human DC activation upon TLR9 stimulation. Methods DCs of patients with XLA and healthy donors were stimulated via TLR4/9 and evaluated for cell activation and cytokine production. Results We showed that BTK plays an essential role in DC responses to unmethylated CpG oligodeoxynucleotide: although responses to lipopolysaccaride/TLR4 induce normal DC activation in terms of upregulation of specific markers (CD86, CD83, CD80, HLA-DR), the CpG/TLR9 pathway is completely impaired in patients with XLA. Furthermore, cytokine production upon TLR9 activation in patients with XLA is radically impaired in terms of IL-6, IL-12, TNF-[alpha], and IL-10 production. Interestingly, BTK mediated STAT1/3 upregulation in a TLR9-dependent manner. The important role of BTK in human DC activation was confirmed after incubation of healthy DCs with ibrutinib, the specific BTK inhibitor, which resulted in impairment of TLR9 responses as seen in patients with XLA. Conclusion Analysis of these data suggests that BTK regulates human DC responses upon TLR9 engagement in terms of activation, cytokine production, and STAT1/3 upregulation. These findings may be of important significance for better understanding and managing different clinical conditions, such as agammaglobulinemia and lymphoid malignancies.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2013.12.1085